Inoue and colleagues have earlier shown that the administration of XPO1 inhibitor, followed by an ATR inhibitor, resulted in profound antitumor effects and prolonged survival in TP53-mutant colorectal cancer models (40). This evidence concerns the gene TP53 and colorectal cancer.